Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | F13A1 | P00488 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | TGM1 | P22735 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 7/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18186369 | 1.00 | HDAC1 (0.44) | HDAC1PARP1GPR119HSD11B1F13A1 | |
| SCHEMBL18186314 | 0.86 | HDAC1 (0.46) | HDAC1PARP1GPR119HSD11B1F13A1 | |
| SCHEMBL18186315 | 0.86 | HDAC1 (0.46) | HDAC1PARP1GPR119HSD11B1F13A1 | |
| SCHEMBL18186350 | 0.86 | HDAC1 (0.46) | HDAC1PARP1GPR119HSD11B1F13A1 | |
| SCHEMBL30890381 | 0.85 | HDAC1 (0.48) | HDAC1PARP1GPR119HSD11B1F13A1 | |
| SCHEMBL30890302 | 0.85 | HDAC1 (0.48) | HDAC1PARP1GPR119HSD11B1F13A1 | |
| SCHEMBL18186207 | 0.84 | HDAC1 (0.45) | HDAC1PARP1GPR119HSD11B1F13A1 | |
| SCHEMBL18186206 | 0.84 | HDAC1 (0.45) | HDAC1PARP1GPR119HSD11B1F13A1 | |
| SCHEMBL18186374 | 0.84 | GPR119 (0.45) | HDAC1PARP1GPR119HSD11B1F13A1 | |
| SCHEMBL18186371 | 0.84 | GPR119 (0.45) | HDAC1PARP1GPR119HSD11B1F13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | HDAC1 942/4885PARP1 501/4885GPR119 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.